LoQus23 Therapeutics Ltd ("LoQus23"), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington's Disease ...
A research team presents an overview of recent advances in the microbial biosynthesis of L-tryptophan (L-Trp) and its ...
Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi's long-term commitment to ...
Researchers are uncovering how disrupted glutamatergic synapses drive diverse forms of intellectual disability, revealing new ...
AZoLifeSciences on MSN
Synthetic biology and metabolic engineering drive microbial L-tryptophan biomanufacturing
This review synthesizes progress in pathway optimization, regulatory rewiring, and microbial cell factory design that has ...
Sanofi has secured regulatory approval in China for two innovative medicines, Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome. The approvals ...
Myqorzo and Redemplo approved in ChinaApproval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia ...
Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric ...
The bill, which lawmakers passed in June, will be modified to more closely match a similar law in California, at Big Tech’s urging. By Benjamin Oreskes Gov. Kathy Hochul of New York signed legislation ...
The Council today formally adopted a targeted revision of the EU regulation on deforestation-free products (EUDR), aimed at simplifying its implementation and ensuring that operators, traders and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback